· Singmed self-developed device

· Single Dose Capsule DPI

· The self-developed Breezhaler® designed and manufactured by Singmed has been conducting Bioequivalence Researching (loaded with Indacaterol/Glycopyrronium Bromide/Indacaterol Maleate and Glycopyrronium Bromide produced by NOVARTIS) with a number of Chinese leading listed pharmaceutical companies, and has realized the replacement of the novel device (Seebri®/Onbrez®/Ultibro® produced by NOVARTIS).

· The self-developed device innovated by Singmed circumvents the patent restrictions of the novel product, incorporating an innovating design and gaining our own patent while maintaining the same aerodynamic mechanism as the novel product.

· Inspiratory resistance range 0.03 to 0.06（kPa·s/L）